Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220649 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
A Phase 1 study of Pancreatic Neoplasms, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00220649: Completed Phase 1 study of Pancreatic Neoplasms, sponsored by St. Luke's-Roosevelt Hospital Center.
NCT00220649 is a Phase 1 study of Pancreatic Neoplasms that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 25 participants, below the 601-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00220649, a Phase 1 study of Pancreatic Neoplasms, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.
Conditions Studied
Interventions
- DRUG gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
Study Locations (1)
New York
- St. Luke's-Roosevelt Hospital Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
What the finished NCT00220649 record still lists
NCT00220649 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 601-participant average among 30 other Pancreatic Neoplasms trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pancreatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin is the first listed.
NCT00220649 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00220649 about?
NCT00220649 is a clinical study titled "Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas". The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.
What is the current status of trial NCT00220649?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2004-03.
What conditions does trial NCT00220649 study?
This clinical trial studies the following conditions: Pancreatic Neoplasms.
What interventions are being tested in trial NCT00220649?
The interventions under investigation include: gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00220649?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00220649 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00220649's enrollment target sits among peer trials
25 25th of 30 higher than 6 of 30 other Pancreatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
-
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia